A new stage of European integration: signing of memorandums with pharmaceutical agencies in Poland and Sweden

Yesterday, on July 2, 2024, during a trilateral meeting in Warsaw, the Ministry of Health of Ukraine, the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Poland (URPL, WMiPB) and the Swedish Medical Products Agency (Läkemedelsverket) signed memoranda of cooperation.

The joint efforts to establish a strong state control body (SCB) in the pharmaceutical industry of Ukraine are the result of friendly relations between the partner countries. They also involve close cooperation of the agencies with the State Expert Center and the State Service on Medicines and Drugs Control. The establishment of the SCB supports Ukraine’s movement towards EU membership and demonstrates the desire of European countries to accept a reliable partner into their community.

Cooperation with the Polish and Swedish agencies will allow us to adopt the European experience in regulating the market of medicines and medical devices. It will contribute to the reform processes of the Ukrainian pharmaceutical industry to create a state control body.

Interaction includes consultations and exchange of experience, seminars, trainings, and conferences. The main areas of cooperation include registration of medicinal products, monitoring of adverse reactions, clinical trials, and inspections of safety systems for medicinal products and medical devices. In addition, this cooperation will facilitate the implementation of European standards in the Ukrainian pharmaceutical industry, which will ensure high quality, safety, and efficacy of medicines and medical devices.

For reference: the creation of a state control body in the pharmaceutical industry is envisaged by the European Integration Law “On Medicines” and is also set as a priority for 2024-2025 by the European Commission. The purpose of the SCB is to implement the state policy in the field of development, market authorization, quality control, safety, and efficacy of medicines and other medical products.